• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Judges skeptical of $60M NeuroVision win over NuVasive | MassDevice.com Legal News

Judges skeptical of $60M NeuroVision win over NuVasive | MassDevice.com Legal News

June 8, 2012 By MassDevice staff

NuVasive logo

A trio of federal judges this week expressed skepticism over a $60 million trademark infringement win NeuroVision Medical Products logged against NuVasive Inc. (NSDQ:NUVA) in 2010.

NuVasive appealed the decision, arguing in March that the judge who handled the case "fundamentally misunderstood trademark law" and "exhibited hostility toward NuVasive’s counsel in front of the jury."

In a June 5 hearing before Judges Jay Bybee, Kim Wardlaw and Betty Fletcher of the U.S. Court of Appeals for the 9th Circuit, NuVasive argued that Judge Manuel Real of the U.S. District Court for Central California obstructed NuVasive’s arguments, tainted its rapport with the jury and seeded a false ruling by giving the jury improper information on what defined misconduct in the case and how damages should legally be determined.

The judges questioned whether Real properly instructed the jury before the verdict.

"It doesn’t even look like the question that was put to the jury, much less the instruction, was properly formulated," Bybee said. "If [Real] has formulated the question wrongly for the jury, wouldn’t that be the best evidence that [he] didn’t understand what the law required?"

In October 20010, San Diego, Calif.-based NuVasive lost the first round in the case over use of the NeuroVision name on some of NuVasive’s neuromonitoring products.

The $60 million award was calculated as a measure of all of NuVasive’s profits from its nerve monitors, according to the documents, rather than profits gained by NuVasive’s allegedly unlawful use of the NeuroVision name. NuVasive was also barred from using the NeuroVision name and ordered to cancel any trademark registrations for it.

In its appeal, NuVasive argued that NMP failed to prove that it had ownership, geographic rights or continuous use of the name, attesting that Judge Real tainted the case and the subsequent jury judgment by wrongfully excluding evidence, giving the jury improper instructions, interrupting NuVasive’s statements and prohibiting NuVasive’s counsel from responding to arguments.

NuVasive wants the 9th Circuit to overturn all of the lower court’s rulings, or at least remand the case to retrial, with a caveat: There must be a new judge.

"There can be no question that Judge Real ignored governing trademark law. He instead tried the case according to his own conception of what the law should be – for which he affirmatively invited this court’s review," NuVasive’s lawyers said in court documents. "Judge Real should have entered judgment as a matter of law in favor of NuVasive. This court should do so now. At the very least, a new trial is required to give NuVasive its day in court before a judge who applies the correct legal standards, does not wrongly restrict NuVasive’s ability to defend itself, and is not openly hostile to its counsel in front of the jury."

NuVasive is also mired in a legal battle against med-tech titan Medtronic (NYSE:MDT), which landed a $101 million patent infringement win against NuVasive for sales of spinal implants that a jury found to infringe Medtronic patents last year.

NuVasive said it plans to “promptly” file an appeal of that ruling as well.

 In re Baxter International: Lather. Rinse. Repeat.

"It just got it easier for infringers to use re-examination as a way to wash a judicial patent validity determination right out of their hair," writes Ron Schutz of Robins, Kaplan, Miller & Ciresi. "En banc reconsideration may be the only way to treat patent law’s latest case of split ends."
Read more

 Catheter Connections slaps Ivera with 2 suits

Catheter Connections said it filed 2 lawsuits in the U.S. District Court for Utah accusing Ivera Medical of patent Infringement, unfair competition, deceptive practices and false advertising.
Read more

 Statute of limitations nears for DePuy ARS suits

The window for filing personal injury lawsuits against Johnson & Johnson (NYSE:JNJ) subsidiary
DePuy Orthopaedic over its recalled ASR metal-on-metal hip implant is closing as the statute of limitations draws near, 2 years after the recall.
Read more

 Ex-Spectranetics CEO Schulte talked himself into trouble
It’s seldom a good idea to voluntarily speak with criminal investigators without a lawyer, writes John Fleder of Hyman, Phelps & McNamara. Ex-Spectranetics CEO John Schulte found that out the hard way when a jury convicted him of making a false statement during an FBI raid.
Read more

 Jury convicts 5 in $205M Medicare scam
A Florida federal jury convicted 2 Florida docs and 3 others of participating in a scheme to bilk Medicare to the tune of $205 million.
Read more

Filed Under: Legal News, News Well, Patent Infringement Tagged With: Legal Roundup, NeuroVision Medical Products Inc., Nuvasive, Trademark Infringement

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy